Roswell Park Cancer Institute (RPCI) requests renewal of its National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) for years 27-31. This application reflects significant changes in leadership, faculty, programmatic and scientific direction, facilities and governance over the past few years. RPCI has, under the leadership of David C. Hohn, MD, President and CEO, recruited new senior leaders for basic, clinical, translational and population science. The CCSG scientific enterprise has been consolidated into five programs and 14 shared resources. These CCSG Programs now include Therapeutics, Biophysical Therapies, Tumor Immunology, Genetics and Cancer Prevention; four of these programs are under new leadership. The Institute has increased its scientific capabilities through the recruitment of 43 new members to CCSG Programs in both the laboratory and clinical research areas. With these recruitments and existing strength, peer-reviewed grant funding has significantly increased in the past year. RPCI and programmatic strategic planning has generated an overall Institute strategy for growth and direction with programmatic strategies targeted toward scientific excellence and multidisciplinary approaches. The overall vision of RPCI over the next five years will focus on the identification, validation and exploitation of targets for cancer treatment and control based on substantial inter-programmatic efforts from all of the Programs. To accommodate the growth of the CCSG membership, development of a new 170,000 gross square feet basic research laboratory building is underway and will be finished by 2005. We are requesting $3.0 million which will support five scientific programs, 14 shared resources, leadership, developmental funds, planning and evaluation and administration. Recruitment, reorganization and institutional commitment have reinvigorated RPCI as a comprehensive cancer center with focused vision for the future and for the development of excellence in all aspects of cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-27
Application #
6677294
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2008-04-30
Budget Start
2003-09-08
Budget End
2004-04-30
Support Year
27
Fiscal Year
2003
Total Cost
$3,276,134
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Chen, George L; Hahn, Theresa; Wilding, Gregory E et al. (2018) Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. Biol Blood Marrow Transplant :
Khoury, Thaer; Gaudioso, Carmelo; Fang, Yisheng V et al. (2018) The role of skin ulceration in breast carcinoma staging and outcome. Breast J 24:41-50
Griffiths, Elizabeth A; Srivastava, Pragya; Matsuzaki, Junko et al. (2018) NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clin Cancer Res 24:1019-1029
Irons, Eric E; Lau, Joseph T Y (2018) Systemic ST6Gal-1 Is a Pro-survival Factor for Murine Transitional B Cells. Front Immunol 9:2150
Travers, Mark J; Kulak, Jessica A; Vogl, Lisa (2018) Waterpipe cafés are hazardous to your health: Determination of a waterpipe specific calibration factor. Int J Hyg Environ Health 221:48-53
Khoury, Thaer; Nagrale, Vidya; Opyrchal, Mateusz et al. (2018) Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy. Appl Immunohistochem Mol Morphol 26:523-532
Yang, Lu; Bhattacharya, Arup; Li, Yun et al. (2018) Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. Oncotarget 9:5614-5626
Hanif, Ahmad; Wang, Eunice S; Thompson, James E et al. (2018) Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. Leuk Lymphoma 59:2011-2013
Welliver, R Ross; Polanco, Jessie J; Seidman, Richard A et al. (2018) Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci :
Widman, Christy A; Rodriguez, Elisa M; Saad-Harfouche, Frances et al. (2018) Clinician and Parent Perspectives on Educational Needs for Increasing Adolescent HPV Vaccination. J Cancer Educ 33:332-339

Showing the most recent 10 out of 1555 publications